RESEARCH PAPER

Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities

  1. Renaud Prudent1,2,†,
  2. Émilie Vassal-Stermann2,†,
  3. Chi-Hung Nguyen3,
  4. Marjorie Mollaret2,
  5. Jean Viallet1,
  6. Agnès Desroches-Castan4,
  7. Anne Martinez1,
  8. Caroline Barette2,
  9. Catherine Pillet2,
  10. Glaucio Valdameri5,
  11. Emmanuelle Soleilhac2,
  12. Attilio Di Pietro5,
  13. Jean-Jacques Feige4,
  14. Marc Billaud1,
  15. Jean-Claude Florent6,
  16. Laurence Lafanechère1,2,*

Article first published online: 16 JAN 2013

DOI: 10.1111/j.1476-5381.2012.02230.x

Issue

British Journal of Pharmacology

British Journal of Pharmacology

Volume 168, Issue 3, pages 673–685, February 2013

Additional Information

How to Cite

Prudent, R., Vassal-Stermann, É., Nguyen, C.-H., Mollaret, M., Viallet, J., Desroches-Castan, A., Martinez, A., Barette, C., Pillet, C., Valdameri, G., Soleilhac, E., Di Pietro, A., Feige, J.-J., Billaud, M., Florent, J.-C. and Lafanechère, L. (2013), Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities. British Journal of Pharmacology, 168: 673–685. doi: 10.1111/j.1476-5381.2012.02230.x

Author Information

  1. 1

    Institut Albert Bonniot, CRI INSERM/UJF U823, La Tronche Cedex, France

  2. 2

    CEA, DSV, iRTSV/CMBA, Grenoble, France

  3. 3

    UMR 176 CNRS-Institut Curie, Institut Curie Bât 110, Orsay, France

  4. 4

    INSERM, Unit 1036, Biology of Cancer and Infection, Grenoble, France

  5. 5

    Equipe Labellisée Ligue 2009, Institut de Biologie et Chimie des Protéines FR 3302, BM2SI UMR 5086 CNRS/Université Lyon 1, Lyon, France

  6. 6

    UMR 176 CNRS-Institut Curie, Centre de Recherche, Paris, France

  1. †

    Contributed equally to this work.

* Correspondence
Laurence Lafanechère, Equipe 3 ‘Polarité, Développement et Cancer’, Institut Albert Bonniot, Rond Point de la Chantourne, 38700 La Tronche, France. E-mail: laurence.lafanechere@ujf-grenoble.fr

  1. †

    Contributed equally to this work.

Publication History

  1. Issue published online: 16 JAN 2013
  2. Article first published online: 16 JAN 2013
  3. Accepted manuscript online: 25 SEP 2012 02:25AM EST
  4. Manuscript Accepted: 10 AUG 2012
  5. Manuscript Revised: 20 JUL 2012
  6. Manuscript Received: 11 APR 2012

Funded by

  • Centre National pour la Recherche Scientifique
  • Commissariat à l'Energie atomique
  • Institut Curie
  • Alliance des Recherches sur le Cancer (an initiative of the Association pour la Recherche sur le Cancer)
  • Rhône-Alpes Region

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (2388K)
FilenameFormatSizeDescription
bph2230-sup-0001-si.zip1425K

Figure S1 Reversibility of CM01 and CM02 effects in HeLa cells. HeLa cells were treated for 2 h with 0.25% DMSO (control); 5 μM colchicine; 10 μM nocodazole, 25 μM nocodazole, 25 μM CM01 or 25 μM CM02, as indicated. Compounds were the removed and cells were incubated overnight in fresh medium. They were then fixed and stained for α-tubulin.

Table S1 Flow chart of the automated screening of the library and the subsequent analysis of active compounds.

Appendix S1 Cell lines and culture.

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

View Full Article with Supporting Information (HTML) Get PDF (2388K)